Additionally, the NRG-GU008 trial is currently randomizing prostate cancer patients with pathologic node-positive disease following radical prostatectomy and a detectable PSA to receive treatment intensification with abiraterone/prednisone and apalutamide [38]. This evidence concerns the gene KLK3 and prostate carcinoma.